Brokerages Set Cognition Therapeutics, Inc. (NASDAQ:CGTX) Target Price at $7.13

Cognition Therapeutics, Inc. (NASDAQ:CGTX) has received a consensus rating of “Buy” from the six research firms that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $7.13.

Several equities research analysts recently commented on CGTX shares. HC Wainwright cut their target price on Cognition Therapeutics from $6.00 to $5.00 and set a “buy” rating on the stock in a research report on Monday, March 24th. B. Riley raised shares of Cognition Therapeutics from a “neutral” rating to a “buy” rating and raised their price target for the company from $1.00 to $1.50 in a report on Thursday, December 19th. Brookline Capital Management upgraded Cognition Therapeutics to a “strong-buy” rating in a research report on Monday, January 27th. Finally, Chardan Capital decreased their price objective on shares of Cognition Therapeutics from $11.00 to $8.00 and set a “buy” rating on the stock in a research report on Friday, March 21st.

Cognition Therapeutics Trading Down 8.2 %

CGTX stock opened at $0.35 on Thursday. The firm has a market capitalization of $21.95 million, a PE ratio of -0.37 and a beta of 1.01. Cognition Therapeutics has a one year low of $0.34 and a one year high of $2.95. The firm has a 50-day moving average of $0.52 and a two-hundred day moving average of $0.54.

Cognition Therapeutics (NASDAQ:CGTX) last released its earnings results on Thursday, March 20th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.01). During the same period in the previous year, the company posted ($0.27) earnings per share. On average, equities research analysts anticipate that Cognition Therapeutics will post -0.8 earnings per share for the current year.

Institutional Trading of Cognition Therapeutics

Hedge funds have recently modified their holdings of the stock. SG Americas Securities LLC purchased a new stake in shares of Cognition Therapeutics in the fourth quarter valued at approximately $26,000. Virtu Financial LLC acquired a new stake in shares of Cognition Therapeutics in the third quarter worth $27,000. Two Sigma Investments LP raised its position in Cognition Therapeutics by 372.2% in the fourth quarter. Two Sigma Investments LP now owns 53,691 shares of the company’s stock valued at $38,000 after purchasing an additional 42,321 shares during the period. Geode Capital Management LLC raised its holdings in shares of Cognition Therapeutics by 8.9% during the 4th quarter. Geode Capital Management LLC now owns 352,348 shares of the company’s stock valued at $247,000 after buying an additional 28,705 shares during the period. Finally, Voss Capital LP acquired a new position in shares of Cognition Therapeutics during the fourth quarter worth $351,000. Hedge funds and other institutional investors own 43.35% of the company’s stock.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.